Table 3 The relationship between the grade of CIL and relapse-free survival (RFS)
Characteristics | Number(n,%) | Events(n,%) | II/III vs. 0/I | II/III vs. IV | IV vs. 0/I | |||
|---|---|---|---|---|---|---|---|---|
HR, 95%CI | P-value | HR, 95%CI | P-value | HR, 95%CI | P-value | |||
Menstrual status | ||||||||
Premenstrual | 280(63.3) | 38(8.6) | 0.821[0.331,2.038] | 0.671 | 1.618[0.697,3.757] | 0.263 | 0.507[0.168,1.535] | 0.230 |
Postmenstrual | 162(36.7) | 32(7.2) | 1.849[0.432,7.922] | 0.407 | 1.237[0.579,2.644] | 0.583 | 1.495[0.327,6.825] | 0.604 |
Clinical stagea | ||||||||
I/II | 289(65.4) | 31(7.0) | 2.373[0.546,10.304] | 0.249 | 1.432[0.608,3.376] | 0.411 | 1.657[0.336,8.163] | 0.535 |
III | 153(34.6) | 39(8.8) | 0.673[0.273,1.657] | 0.389 | 1.423[0.677,2.990] | 0.352 | 0.473[0.171,1.304] | 0.148 |
Molecular type | ||||||||
HR+ | 280(63.3) | 45(10.2) | 0.936[0.406,2.156] | 0.876 | 1.847[0.872,3.915] | 0.109 | 0.506[0.188,1.368] | 0.180 |
HER2+ | 182(41.2) | 25(5.7) | 0.748[0.216,2.592] | 0.647 | 1.484[0.580,3.798] | 0.411 | 0.504[0.124,2.043] | 0.338 |
TN | 83(18.8) | 13(2.9) | NA | 0.998 | 0.634[0.201,2.007] | 0.439 | NA | 0.998 |
N stage | ||||||||
N2/N3 | 151(34.2) | 38(8.6) | 0.682[0.277,1.679] | 0.400 | 1.592[0.736,3.441] | 0.237 | 0.428[0.152,1.206] | 0.108 |
N0/N1 | 291(65.8) | 32(7.2) | 2.348[0.541,10.193] | 0.254 | 1.2511[0.553,2.829] | 0.591 | 1.877[0.390,9.049] | 0.432 |
T stage | ||||||||
T3 | 29(6.6) | 8(1.8) | 0.580[0.067,5.046] | 0.622 | 0.435[0.083,2.283] | 0.325 | 1.332[0.120,14.740] | 0.815 |
T2 | 261(59.0) | 44(10.0) | 1.145[0.439,2.983] | 0.782 | 1.203[0.598,2.416] | 0.604 | 0.952[0.328,2.760] | 0.928 |
T1 | 152(34.4) | 18(4.1) | 1.136[0.238,5.413] | 0.873 | 2.058[0.653,6.482] | 0.218 | 0.552[0.098,3.117] | 0.501 |